SDZ 259158
Latest Information Update: 04 Aug 1998
At a glance
- Originator Novartis
- Class Antihyperglycaemics
- Mechanism of Action Carnitine O-palmitoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Aug 1998 No-Development-Reported for Type-2 diabetes mellitus in USA (Unknown route)
- 13 Jan 1997 New profile
- 13 Jan 1997 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)